IgG4-related disease (IgG4-RD) is a recently recognized disease entity characterized by high serum IgG4 concentrations and infiltration of IgG4 + plasma cells with hyperplastic ectopic germinal centres at affected sites. Although the underlying immune mechanism of this disease remains unclear, T cells are abundantly present at affected sites and key players in IgG4-RD pathogenesis. The role of T cell subsets has been investigated thoroughly in this disease. Recent advances in this field have clarified the importance of T follicular helper cells. In this review, we describe the role of T follicular helper cells in the disease process of IgG4-RD, in particular, for IgG4 class-switching, plasmablast and plasma cell differentiation, and germinal centre formation.
Introduction
IgG4-related disease (IgG4-RD) affects various organ systems and is characterized by elevated serum IgG4 levels, tissue infiltration by IgG4 + plasma cells and storiform fibrosis [14] . The underlying pathogenesis of IgG4-RD remains largely unknown. A better understanding of this disease is necessary for identifying therapeutic targets. Since large numbers of T cells are present at affected sites, T cells are involved in the pathogenesis of this disease. Evidence implicating T cells in IgG4-RD has been increasing, and the role of T cell subsets have been clarified. Ectopic germinal centres appear at affected sites and local B cells produce IgG4. T follicular helper (Tfh) cells help B cell maturation and Ig isotype-switching at germinal centres. Of note, recent investigations have revealed the importance of Tfh cells in the pathophysiology of IgG4-RD. In this review we discuss the pathogenic role of Tfh cells as well as the other T cell subsets in IgG4-RD.
The differences between T helper cells and Tfh cells
It would be helpful to understand the major differences between T helper (Th) and Tfh cells because Tfh cells are specialized providers of B cell help and germinal centre development [5, 6] . B cell lymphoma 6 (Bcl-6) has been demonstrated as the master regulator of Tfh cell differentiation because the deletion of Bcl-6 results in the absence of Tfh cells, but normal development of the other Th cell subsets [79] . Accordingly, Bcl-6 is highly expressed in Tfh cells and is also known to be an antagonistic transcription factor for B lymphocyteinduced maturation protein 1 (Blimp-1), the transcription factor highly expressed in Th cell subsets other than Tfh cells [79] .
The chemokine receptor CXC chemokine receptor 5 (CXCR5) is a central marker of Tfh cells, which is required for Tfh cells to migrate into germinal centres via interactions with its ligand CXC chemokine ligand 13 (CXCL13) [6] . CXCL13 is also expressed at high levels by Tfh cells (but not by other Th cells) in humans [6] .
The transcription factor achaete-scute homologue 2 (Ascl2) is selectively upregulated in Tfh cells in vivo [10] . Ascl2 upregulates CXCR5 (but not Bcl-6) in T cells to induce T cell migration into the germinal centres [10] , whereas Ascl2 acts as a suppresser of Th1, Th2 and Th17 cell differentiation. At the TB border, B cells provide another signal for precursor Tfh cells to upregulate Bcl-6 expression for the completion of Tfh cell polarization and germinal centre formation [10] .
Signalling lymphocytic activation molecule (SLAM)-associated protein (SAP) is critical for Tfh cell and germinal centre development [6] . SAP plays a role in TfhB interaction by binding to the intracellular domains of SLAM family surface receptors [6] .
Programmed death (PD)-1 is generally expressed on activated T cells, including Tfh cells. PD-1 is an inhibitory receptor essential for T cell tolerance, but PD-1 expressed by Tfh cells plays a role in B cell selection via direct inductive signals to B cells [6] .
Inducible T-cell co-stimulator (ICOS) has roles in Tfh cell differentiation, migration, cytokine production and germinal centre formation [11, 12] . B cells also express ICOS ligand, which is required for germinal centre formation.
IL-21 is the most important Tfh cell cytokine for driving plasmablast and plasma cell differentiation in germinal centres [13] . IL-4 from Tfh cells (but not from Th2 cells) plays a role in class-switch recombination [14, 15] . Moreover, the deletion of Th2-related genes does not result in a loss of germinal centres [16, 17] , whereas the deletion of both IL-4 and the IL-21 receptor resulted in a loss of germinal centres [13] , suggesting that both IL-4 and IL-21 from Tfh cells are required for germinal centre development and maintenance. Germinal centres are the primary location for antigen-specific B cell proliferation, mutation and differentiation and Ig class-switching [6] .
In summary, distinguishing features of Tfh cells from the other Th cells include the expression of Bcl-6, CXCR5, Ascl2, SAP, PD-1, ICOS, IL-21 and IL-4, in concert with the absence of Blimp-1 (Table 1) .
Th1 cells
Th1 cells play a role in cell-mediated immune responses, including production of IFN-g (which leads to the activation of macrophages and cytotoxic T cells [52, 53] . No study has reported a functional analysis of Treg cells from patients with IgG4-RD, and direct evidence of IgG4 class-switching by Treg cells is required in the future.
Involvement in fibrosis
Another important point about the presence of Treg cells in IgG4-RD is their possible involvement in the pathogenesis of fibrosis through TGF-b secretion. Although the induction of extracellular matrix components by TGF-b is crucial during wound healing and tissue repair, overproduction of TGF-b leads to fibrosis [54] . 
CD8 + T cells
Tissue destruction caused by the cytolytic mediator perforin, the serine protease granzyme or Fas lytic pathways from CD8 + T cells is more important in SS than IgG4-related dacryoadenitis and sialadenitis, so-called Mikulicz disease. However, the number of IFN-g + CD8 + T cells in peripheral blood was reported to be increased in IgG4-RD [18] with a similar extent of CD8 + T cell infiltration at affected sites between IgG4-RD and SS [57] . Importantly, the frequency of expression of perforin and granzyme B by CD8 + T cells was lower in IgG4-RD, whereas the frequency of expression of the immunoinhibitory receptor PD-1 by the same cells was higher in IgG4-RD compared with in SS [57] , suggesting that CD8 + T cells are exhausted in IgG4-RD. In fact, expression of the apoptosis mediator Fas (CD95)Fas ligand in lymphocytes was higher at affected sites in patients with SS compared with in patients with Mikulicz disease [58, 59] . Moreover, circulating lymphocytes in Mikulicz disease showed a defect in cytotoxic capacity [59] . As a result, although both diseases involve lymphocytic infiltration, only the acinar cells in SS undergo apoptosis [58] . Thus, acinar cell apoptosis by CD8 + T cells is involved in the pathogenesis of SS but not of Mikulicz disease.
Cytotoxic CD4 + T cells
Cytotoxic CD4 + T cells are classically known as the CD28 low subpopulation among CD4 + T cells, and they secret Th1-like and proinflammatory cytokines [60] . The expansion of this T cell subset at affected sites and in peripheral blood has been initially described in patients with granulomatosis with polyangiitis, and their numbers correlate with the total number of affected organs, [76, 79] . In functional analysis, IL-4secreting Tfh cells promoted class-switch recombination of antibodies, whereas IL-21secreting Tfh cells were essential for promoting somatic hypermutation in B cells [76, 79] . Thus, enhanced Tfh cell activity (via distinct cytokine profiles with different localization) participates in B cell selection and proliferation, germinal centre formation and IgG4 class-switching. IgG4-RD patients have a significantly higher number and size of ectopic germinal centres and higher expression of Bcl-6 mRNA at affected sites [78, 80, 81] . CXCL13 and CXCR5 are also upregulated at affected sites, indicating that CXCL13CXCR5 interactions play a role in migration of Tfh cells into affected sites [78, 82, 83] . Indeed, follicular dendritic cells that produce CXCL13 were present within ectopic germinal centres at sites of IgG4-RD [84] Circulating Tfh cells contain three major subsets according to their differential expression of the chemokine receptors CXCR3 and CCR6: Tfh1, Tfh2 and Tfh17 cells [92] . These three subsets are functionally distinct with respect to their transcriptional and cytokine properties and their abilities to support a humoral response.
PD-1 is a member of the CD28 family, negative regulators of T cell activation. Importantly, PD-1 is highly expressed by activated Tfh cells, and is involved in B cell selection and survival in germinal centres [93] . CCR7 controls T cell migration towards lymphoid tissues through interaction with its ligands CCL19 and CCL21. The expression of CCR7 on T cells is downregulated when they are activated to migrate into sites of inflammation [94] . Recent We found a significant positive correlation between the number of Tfh2 cells and serum levels of IL-4, and that the two patients with the highest levels of IL-21 had the highest numbers of plasmablasts, serum IgG4 levels and Tfh2 cell numbers in active, untreated IgG4-RD [26, 39] . Thus, activated Tfh2 cells more efficiently secrete IL-4 and IL-21 to induce enhanced IgG4 production through plasmablast differentiation [26, 39] . IL-10 is also known as a potential cytokine for IgG4 class-switching, but there was no correlation between serum IgG4 and IL-10 levels [39] .
The other pathological role of Tfh2 cells in IgG4-RD IL-21 from Tfh cells is essential for germinal centre formation [6, 13]. Indeed, IL-21 mRNA expression was increased, positively correlating with the number of hyperplastic ectopic germinal centre formations in IgG4-RD [78, 80] . IL-21secreting lymphocytes also expressed IL-4, Bcl-6 and CXCR5 [78] , suggesting that IL-21secreting lymphocytes are Tfh2 cells. Thus, excessive IL-21 production from Tfh2 cells may induce hyperplastic germinal centre formations in IgG4-RD.
The possible mechanism of increased Tfh2 cells in IgG4-RD IgG4-RD responds well to glucocorticoid treatment, but tapering or cessation of treatment often leads to relapse [102] . In this regard, while activated Tfh2 cell counts, plasmablast counts and levels of serum IgG4 and IL-4 decrease after glucocorticoid treatment in parallel with disease improvement, total Tfh2 cell counts remain unchanged [26, 39] , suggesting that increased total Tfh2 cells are the underlying pathogenic mechanism and contribute to incomplete cure of IgG4-RD. Tfh cell differentiation is induced by chronic antigen stimulation in secondary lymphoid organs and by a combination of cytokines [103] . On this point, since circulating Tfh2 cells in IgG4-RD have a memory phenotype, as evidenced by their decreased expression of CD45RA [26, 39] , chronic stimulation by unknown antigens (such as allergens) is one factor promoting Tfh2 cell differentiation. Interestingly, chronic exposure to occupational antigens may play a role in the initiation and/or maintenance of IgG4-RD [104] . The increased IgG4 response to food and animal antigens also deserves attention [105] .
IgG4 itself is generally thought to be non-inflammatory because it does not crosslink antigens and fix complement by the process called Fab-arm exchange [106] . Furthermore, from the viewpoint of allergy (which is frequently observed in IgG4-RD), the emergence of IgG4 is associated with a decrease in allergic symptoms through an allergen-blocking effect [106] . However, according to recent evidence showing pathogenic effects of IgG4 itself from IgG4-RD [107] , Tfh2 cells that induce IgG4 production from plasmablasts are the potential therapeutic target in this disease. Indeed, the efficacy of abatacept in a patient with IgG4-RD may be explained by inhibition of Tfh cells with respect to B cell interaction and subsequent disruption of the formation of ectopic germinal centres [108, 109] . Although it is still unclear whether IgG4-RD is an autoimmune disease or an allergic disorder, the detection of IgG4-recognizing autoantigens or exogenous antigens may contribute to a more thorough elucidation of the pathophysiology of IgG4-RD.
Circulating Tfh1 cells in IgG4-RD
We have made another important observation: that Tfh1 cells were also increased and activated in IgG4-RD [26] . Activated Tfh1 cells positively correlated with disease activity, but not with serum IgG4 levels, suggesting that they play a role in the pathogenesis of IgG4-RD, but are not involved in IgG4 production. Although the precise function of Tfh1 cells remains unclear, they express CXCR5 and the transcription factor T-bet, and produce IFN-g [92] . Thus, they migrate to the ectopic germinal centres that express CXCL13 (the ligand for CXCR5) and produce IFN-g at affected sites, resulting in tissue fibrosis.
Circulating Tfh17 cells in IgG4-RD
The number of circulating Tfh17 cells and their activated phenotype was not increased in IgG4-RD [26, 39] . Furthermore, the number of these Tfh17 cells did not correlate with the level of serum IgG4 or the number of circulating plasmablasts [26] . Moreover, IL-17 (which is the hallmark of Tfh17 cells) is rarely expressed at affected sites [78] . Collectively, Tfh17 cells may not be involved in the pathogenesis of IgG4-RD.
Conclusions
Recently accumulated findings have clarified that T cells are involved in the pathogenesis of IgG4-RD (Table 2) . Tfh2 cells are important in germinal centre formation, as well as in plasmablast and plasma cell differentiation and IgG4 class-switching (Fig. 1) . Future insights into T cell immunology and pathophysiology should lead to novel treatments for this disease.
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